Clinical Trials Browser

Phase 2 × IMC-18F1 × Genitourinary × Clear all

NCT01282463 2019-09-09

Study of Ramucirumab or Icrucumab (IMC-18F1) With Docetaxel or Docetaxel Alone as Second-Line Therapy in Participants With Bladder,Urethra, Ureter, or Renal Pelvis Carcinoma

Phase 2 Completed

148 enrolled 19 charts

Carcinoma, Renal Cell, Ureteral Neoplasms, Urethral Neoplasms